Arvinas
$7.47
52
-$0.11-1.45% Today
Statistics
Day High
7.83
Day Low
7.47
52W High
14.51
52W Low
6.06
Volume
28,998,694
Avg. Volume
-
Mkt Cap
479.75M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
30JulExpected
Expected EPS
-0.368893
Actual EPS
N/A
Financials
-75.51%Profit Margin
Unprofitable526.8MRevenue
-397.8MNet Income
Analyst Ratings
18.33Average Price Target
The highest estimate is 24.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy 83%
Hold 17%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ARVN. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap191.7B
Gilead Sciences
GILD
Mkt Cap155.93B
Bristol-Myers Squibb
BMY
Mkt Cap116.66B
Novartis
NVS
Mkt Cap292.07B
Merck
MRK
Mkt Cap294.03B
Pfizer
PFE
Mkt Cap149.38B
Abbvie
ABBV
Mkt Cap402.35B
Roche
RHHBY
Mkt Cap332.67B
Lilly(Eli) &
LLY
Mkt Cap1.01T
Regeneron Pharmaceuticals
REGN
Mkt Cap64.18B
About
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Show more...
CEO
Mr. Andrew R. Saik
Employees
430
Country
United States
ISIN
US04335A1051
Listings
0 Comments
Share your thoughts
FAQ
What is Arvinas stock price today?▼
The current price of ARVN is $7.47 USD — it has decreased by -1.45% in the past 24 hours. Watch Arvinas stock price performance more closely on the chart.
What is Arvinas stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Arvinas stocks are traded under the ticker ARVN.
Is Arvinas stock price growing?▼
ARVN stock has risen by +5.03% compared to the previous week, the month change is a -17.29% fall, over the last year Arvinas has showed a +1.62% increase.
What is Arvinas market cap?▼
Today Arvinas has the market capitalization of 479.75M
When is the next Arvinas earnings date?▼
Arvinas is going to release the next earnings report on July 30, 2026.
What were Arvinas earnings last quarter?▼
ARVN earnings for the last quarter are -0.9 USD per share, whereas the estimation was -0.92 USD resulting in a +2.56% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Arvinas revenue for the last year?▼
Arvinas revenue for the last year amounts to 526.8M USD.
What is Arvinas net income for the last year?▼
ARVN net income for the last year is -397.8M USD.
How many employees does Arvinas have?▼
As of June 15, 2026, the company has 430 employees.
In which sector is Arvinas located?▼
Arvinas operates in the Health & Wellness sector.
When did Arvinas complete a stock split?▼
Arvinas has not had any recent stock splits.
Where is Arvinas headquartered?▼
Arvinas is headquartered in New Haven, United States.